Roche Holding : Encore un bon trimestre…. mais 2019 s’annonce difficile
>7% tcc top line au T3 / +1.7% de mieux que les attentes du consensus - Roche affiche de nouveau de belles croissances de ses ventes ce trimestre. Les ventes du groupe progressent de 7% tcc grâce à la Pharma (+7% tcc vs +7% tcc au T2 et au T1) et à la division Diagnostics (+7% tcc vs +7% au T2 et +5% au T1). Les ventes du groupe (13 969 MCHF ressortent ainsi +1.7% supérieures aux attentes du Cs grâce notamment à la franchise des « Big 3 » (MabThera/Rituxan, Herceptin,...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.